Song-Mao Ouyang1, Hong-Quan Zhu1, Ying-Na Xie2, Zhi-Sheng Zou1, Hui-Min Zuo3, Yun-Wei Rao3, Xiao-Yan Liu3, Bin Zhong4, Xin Chen5. 1. Department of Intensive Medicine, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, 341000, China. 2. Department of Pathogenic Biology, School of Basic Medical Sciences, Gannan Medical University, Ganzhou, 341000, China. 3. Department of Respiratory, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, 341000, China. 4. Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, 341000, China. 5. Department of Pathogenic Biology, School of Basic Medical Sciences, Gannan Medical University, Ganzhou, 341000, China. baiyjqqq@126.com.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, and outbreaks have occurred worldwide. Laboratory test results are an important basis for clinicians to determine patient condition and formulate treatment plans. METHODS: Fifty-two thousand six hundred forty-four laboratory test results with continuous values of adult inpatients who were diagnosed with COVID-19 and hospitalized in the Fifth Hospital in Wuhan between 16 January 2020 and 18 March 2020 were compiled. The first and last test results were compared between survivors and non-survivors with variance test or Welch test. Laboratory test variables with significant differences were then included in the temporal change analysis. RESULTS: Among 94 laboratory test variables in 82 survivors and 25 non-survivors with COVID-19, white blood cell count, neutrophil count/percentage, mean platelet volume, platelet distribution width, platelet-large cell percentage, hypersensitive C-reactive protein, procalcitonin, D-dimer, fibrin (ogen) degradation product, middle fluorescent reticulocyte percentage, immature reticulocyte fraction, lactate dehydrogenase were significantly increased (P < 0.05), and lymphocyte count/percentage, monocyte percentage, eosinophil percentage, prothrombin activity, low fluorescent reticulocyte percentage, plasma carbon dioxide, total calcium, prealbumin, total protein, albumin, albumin-globulin ratio, cholinesterase, total cholesterol, nonhigh-density/low-density/small-dense-low-density lipoprotein cholesterol were significantly decreased in non-survivors compared with survivors (P < 0.05), in both first and last tests. Prothrombin time, prothrombin international normalized ratio, nucleated red blood cell count/percentage, high fluorescent reticulocyte percentage, plasma uric acid, plasma urea nitrogen, cystatin C, sodium, phosphorus, magnesium, myoglobin, creatine kinase (isoenzymes), aspartate aminotransferase, alkaline phosphatase, glucose, triglyceride were significantly increased (P < 0.05), and eosinophil count, basophil percentage, platelet count, thrombocytocrit, antithrombin III, red blood cell count, haemoglobin, haematocrit, total carbon dioxide, acidity-basicity, actual bicarbonate radical, base excess in the extracellular fluid compartment, estimated glomerular filtration rate, high-density lipoprotein cholesterol, apolipoprotein A1/ B were significantly decreased in non-survivors compared with survivors (P < 0.05), only in the last tests. Temporal changes in 26 variables, such as lymphocyte count/percentage, neutrophil count/percentage, and platelet count, were obviously different between survivors and non-survivors. CONCLUSIONS: By the comprehensive usage of the laboratory markers with different temporal changes, patients with a high risk of COVID-19-associated death or progression from mild to severe disease might be identified, allowing for timely targeted treatment.
BACKGROUND:Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, and outbreaks have occurred worldwide. Laboratory test results are an important basis for clinicians to determine patient condition and formulate treatment plans. METHODS: Fifty-two thousand six hundred forty-four laboratory test results with continuous values of adult inpatients who were diagnosed with COVID-19 and hospitalized in the Fifth Hospital in Wuhan between 16 January 2020 and 18 March 2020 were compiled. The first and last test results were compared between survivors and non-survivors with variance test or Welch test. Laboratory test variables with significant differences were then included in the temporal change analysis. RESULTS: Among 94 laboratory test variables in 82 survivors and 25 non-survivors with COVID-19, white blood cell count, neutrophil count/percentage, mean platelet volume, platelet distribution width, platelet-large cell percentage, hypersensitive C-reactive protein, procalcitonin, D-dimer, fibrin (ogen) degradation product, middle fluorescent reticulocyte percentage, immature reticulocyte fraction, lactate dehydrogenase were significantly increased (P < 0.05), and lymphocyte count/percentage, monocyte percentage, eosinophil percentage, prothrombin activity, low fluorescent reticulocyte percentage, plasma carbon dioxide, total calcium, prealbumin, total protein, albumin, albumin-globulin ratio, cholinesterase, total cholesterol, nonhigh-density/low-density/small-dense-low-density lipoprotein cholesterol were significantly decreased in non-survivors compared with survivors (P < 0.05), in both first and last tests. Prothrombin time, prothrombin international normalized ratio, nucleated red blood cell count/percentage, high fluorescent reticulocyte percentage, plasma uric acid, plasma ureanitrogen, cystatin C, sodium, phosphorus, magnesium, myoglobin, creatine kinase (isoenzymes), aspartate aminotransferase, alkaline phosphatase, glucose, triglyceride were significantly increased (P < 0.05), and eosinophil count, basophil percentage, platelet count, thrombocytocrit, antithrombin III, red blood cell count, haemoglobin, haematocrit, total carbon dioxide, acidity-basicity, actual bicarbonate radical, base excess in the extracellular fluid compartment, estimated glomerular filtration rate, high-density lipoprotein cholesterol, apolipoprotein A1/ B were significantly decreased in non-survivors compared with survivors (P < 0.05), only in the last tests. Temporal changes in 26 variables, such as lymphocyte count/percentage, neutrophil count/percentage, and platelet count, were obviously different between survivors and non-survivors. CONCLUSIONS: By the comprehensive usage of the laboratory markers with different temporal changes, patients with a high risk of COVID-19-associated death or progression from mild to severe disease might be identified, allowing for timely targeted treatment.
Authors: Dae-Kyum Kim; Benjamin Weller; Chung-Wen Lin; Dayag Sheykhkarimli; Jennifer J Knapp; Guillaume Dugied; Andreas Zanzoni; Carles Pons; Marie J Tofaute; Sibusiso B Maseko; Kerstin Spirohn; Florent Laval; Luke Lambourne; Nishka Kishore; Ashyad Rayhan; Mayra Sauer; Veronika Young; Hridi Halder; Nora Marín-de la Rosa; Oxana Pogoutse; Alexandra Strobel; Patrick Schwehn; Roujia Li; Simin T Rothballer; Melina Altmann; Patricia Cassonnet; Atina G Coté; Lena Elorduy Vergara; Isaiah Hazelwood; Betty B Liu; Maria Nguyen; Ramakrishnan Pandiarajan; Bushra Dohai; Patricia A Rodriguez Coloma; Juline Poirson; Paolo Giuliana; Luc Willems; Mikko Taipale; Yves Jacob; Tong Hao; David E Hill; Christine Brun; Jean-Claude Twizere; Daniel Krappmann; Matthias Heinig; Claudia Falter; Patrick Aloy; Caroline Demeret; Marc Vidal; Michael A Calderwood; Frederick P Roth; Pascal Falter-Braun Journal: Nat Biotechnol Date: 2022-10-10 Impact factor: 68.164
Authors: Diana A Gorog; Robert F Storey; Paul A Gurbel; Udaya S Tantry; Jeffrey S Berger; Mark Y Chan; Daniel Duerschmied; Susan S Smyth; William A E Parker; Ramzi A Ajjan; Gemma Vilahur; Lina Badimon; Jurrien M Ten Berg; Hugo Ten Cate; Flora Peyvandi; Taia T Wang; Richard C Becker Journal: Nat Rev Cardiol Date: 2022-01-13 Impact factor: 49.421
Authors: Roxana Covali; Demetra Socolov; Razvan Socolov; Ioana Pavaleanu; Alexandru Carauleanu; Mona Akad; Vasile Lucian Boiculese; Ana Maria Adam Journal: Diagnostics (Basel) Date: 2021-12-30